MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

MDT

98.84

+0.35%↑

144.96

-0.77%↓

VEEV

219.1

+0.44%↑

HQY

86.84

+1.35%↑

NEOG

9.45

+0.43%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

495.32 -1.83

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

493.96

Max

506.8

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
Winstmarge	-39.75
Werknemers	528
EBITDA	-68M -106M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+25.93% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.4B 12B
Vorige openingsprijs	497.15
Vorige sluitingsprijs	495.32

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 jan 2026, 18:44 UTC

Belangrijke Marktbewegers

Agenus Falls After $141 Million Zydus Deal Closes

15 jan 2026, 17:51 UTC

Belangrijke Marktbewegers

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15 jan 2026, 17:25 UTC

Belangrijke Marktbewegers

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15 jan 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15 jan 2026, 23:40 UTC

Marktinformatie

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15 jan 2026, 23:11 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 jan 2026, 23:11 UTC

Marktinformatie

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15 jan 2026, 23:01 UTC

Marktinformatie

New Zealand's Economy Enters An Upswing -- Market Talk

15 jan 2026, 22:56 UTC

Marktinformatie

Winsten

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15 jan 2026, 22:51 UTC

Marktinformatie

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15 jan 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

15 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

15 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

15 jan 2026, 21:27 UTC

Winsten

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15 jan 2026, 21:15 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Commodities Roundup: Market Talk

15 jan 2026, 21:11 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

15 jan 2026, 21:11 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15 jan 2026, 20:10 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15 jan 2026, 20:04 UTC

Winsten

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15 jan 2026, 20:03 UTC

Marktinformatie

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15 jan 2026, 19:26 UTC

Marktinformatie

Silver Closes at Fresh High -- Market Talk

15 jan 2026, 18:29 UTC

Belangrijke Marktbewegers

Agenus Falls After $141M Zydus Deal Closes

15 jan 2026, 18:20 UTC

Winsten

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15 jan 2026, 17:56 UTC

Marktinformatie

Winsten

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15 jan 2026, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

15 jan 2026, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

15 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

15 jan 2026, 17:02 UTC

Acquisities, Fusies, Overnames

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

25.93% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 636.22 USD 25.93%

Hoogste 900 USD

Laagste 527 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.